Bcl-2 is the prototype of a class of oncogenes which regulates apoptosis. Bcl-2-related gene products with either death-promoting and death-inhibitory activity are critically involved in numerous disease states and thus constitute prime targets for therapeutic interventions. The relative amount of death agonists and antagonists from the Bcl-2 family constitutes a regulatory rheostat whose function is determined, at least in part, by selective protein-protein interactions. Bcl-2 and its homologs insert into intracellular membranes including mitochondria, the endoplasmatic reticulum and the nuclear envelope. Many of the molecular genetic, ultrastructural, crystallographic and functional studies suggest that Bcl-2-related molecules exert their apoptosis-regulatory eects via regulating mitochondrial alterations preceding the activation of apoptogenic proteases and nucleases. Via a direct eect on mitochondrial membranes, Bcl-2 prevents all hallmarks of the early stage of apoptosis including disruption of the inner mitochondrial transmembrane potential and the release of apoptogenic protease activators from mitochondria. The mitochondrial permeability transition (PT) pore, also called mitochondrial megachannel or multiple conductance channel, is a multiprotein complex formed at the contact site between the mitochondrial inner and outer membranes, exactly at the same localization at which Bax, Bcl-2, and Bcl-X L are particularly abundant. The PT pore participates in the regulation of matrix Ca 2+ , pH, DC m , and volume and functions as a Ca 2+ -, voltage-, pH-, and redox-gated channel with several levels of conductance and little if any ion selectivity. Experiments involving the puri®ed PT pore complex indicate that Bax, Bcl-2, and Bcl-X L exert at least part of their apoptosis-regulatory function by facilitating (Bax) or inhibiting (Bcl-2, Bcl-X L ) PT pore opening. These ®ndings clarify the principal (but not exclusive) mechanism of Bcl-2-mediated cytoprotection.
Introduction
The family of Bcl-2-related proteins constitutes one of the biologically most relevant classes of apoptosisregulatory gene products. The bcl-2 (B cell lymphoma/ leukemia-2) gene was identi®ed at the chromosomal breakpoint of t(14;18) bearing B cell lymphomas. Bcl-2 is now known to belong to a growing family of apoptosis-regulatory gene products which may either promote cell survival (Bcl-2, Bcl-X L , Bcl-w, Mcl-1, A1/ B¯-1) or encourage cell demise (Bax, Bak, Bcl-X S , Bad, Bid, Bik, Bim, Hrk, Bok) (Cory, 1995; Kroemer, 1997; Reed, 1994; Thompson, 1995; Yang and Korsmeyer, 1996) . In addition to these human genes, the genomes of several pathogenic viruses code for death-inhibitory Bcl-2 analogs: Epstein ± Barr virus (gene product: BHRF), adenovirus (E1B19K), and Kaposi sarcoma-associated herpes virus 8 (Ksbcl-2). The death antagonistic and death promoting members of the Bcl-2 family function as potential oncogenes and tumor suppressor genes, respectively. Many tumors hyperexpress apoptosis-inhibitory or hypoexpress death-inducing members of the Bcl-2 family. Bcl-2 and its homologs may intervene in oncogenesis at a ®rst level by favoring the persistence of mutated cells that, in normal circumstances, would be eliminated by apoptosis. At this level, Bcl-2 alone has a low transforming potential. It requires the cooperation of other oncogenes (e.g. c-myc) to produce tumors in vivo (Cory, 1995; Reed, 1994; Thompson, 1995; Yang and Korsmeyer, 1996) . At a second level, the Darwinian selection of cancer cells by adverse intrinsic conditions (limited trophic supply, oxygen shortage) and/or therapeutic agents (chemotherapy, radiotherapy) may favor the survival of proliferating cells which overexpress antiapoptotic gene products. In other words, Bcl-2 contributes not only to the origins of cancer but also to the diculties in treating it.
Until recently, the mechanism by which Bcl-2 related proteins regulate apoptosis have remained elusive. Obviously, the knowledge of the subcellular and molecular mechanisms by which Bcl-2 related proteins regulate apoptosis may have important consequences for the therapeutic correction of disorders associated with de®cient apoptosis control. This article will focus on the subcellular and molecular mechanisms via which Bcl-2 and its homologs control apoptosis.
The process of apoptosis ± a few general rules
Three phases of apoptosis: initiation, eector and degradation
The process of apoptosis can be subdivided into a least three dierent phases (Table 1) . During the heterogeneous initiation phase, cells receive apoptosistriggering stimuli. Such death inducers include ligation of certain receptors (Fas/APO-1/CD95, TNF-R, TGF-R, glucocorticoid receptors etc.) or, in the case of obligate growth factor receptors, the absence of receptor occupancy. In addition, interventions on second messenger systems (Ca phosphoinositolphosphates etc.), suboptimal growth conditions (shortage of essential nutrients, hypoxia), mild physical damage (radiotherapy), and numerous toxins (reactive oxygen species, chemotherapy, and toxins stricto sensu) can induce apoptosis (Kroemer et al., 1995; Thompson, 1995) . Non-speci®c or receptormediated death induction involves a stimulus-dependent (`private') biochemical pathway, and it is only after this initiation phase that common pathways come into action. It is generally assumed that the eector phase of apoptosis de®nes the`decision to die' at the`point-of-no-return' of the apoptotic cascade. It is at this level that the dierent private pathways converge into one (or few) common pathway(s) and that cellular processes (redox potentials, expression levels of oncogene products including Bcl-2 related proteins) have still a decisive regulatory function. Once the cell has been irreversibly committed to death, the dierent manifestations classically associated with apoptosis such as DNA fragmentation become detectable. This degradation phase is similar in all cell types. It is characterized by the action of catabolic enzymes, mostly speci®c proteases (caspases, a family cysteine proteases cleaving after Asp residues) and endonucleases, within the limits of a near-tointact plasma membrane. Thus, the cell actively contributes to its removal in a`suicidal' fashion and undergoes stereotyped biochemical and ultrastructural alterations.
The crucial role of mitochondria
Recently, it has become clear that, in contrast to prior belief, mitochondria ful®l an essential role during the execution phase of apoptosis in most if not all models of apoptosis induction (Kroemer et al., 1995 Penninger and Kroemer, 1998) . In many (if not all) models of apoptosis thus far investigated, the barrier function of either of the mitochondrial membranes is lost, leading to the dissipation of the inner transmembrane proton gradient (DC m ) and/or the release of intermembrane proteins such as cytochrome c via the mechanically disrupted outer membrane (vander Heiden et al., 1997). These mitochondrial changes mark the`point of no return' and determine the fate of the cell. Altogether, present data are compatible with a general mechanism of apoptosis in which three phases can be distinguished: (i) a (mostly) pre-mitochondrial phase (induction phase) during which, depending on the apoptosis inducing stimulus, a large variety of signal transduction cascades or damage pathways can be activated; (ii) a mitochondrial phase (eector/decision phase) during which mitochondrial membrane integrity is lost and the`decision to die' is made; and (iii) a post-mitochondrial phase (degradation phase) during which soluble factors released by mitochondria activate catabolic hydrolases responsible for the apoptotic degradation of essential proteins and nuclear DNA ( Table 1) .
The decisive event of cell death ± mitochondria versus caspases
It may be important to note that, in a number of models of apoptosis, inhibition of caspases with broad spectrum inhibitors such as N-benzyloxycarbonyl-ValAla-Asp-¯uoromethylketone (Z-VAD.fmk) fails to prevent the disruption of mitochondrial membrane function and subsequent cytolysis, despite the fact that Z-VAD.fmk does prevent the acquisition of the apoptotic morphology and of several biochemical hallmarks of apoptosis including endonuclease activation (Hirsch et al., , 1998a Xiang et al., 1996) . Although caspases are essential signalling molecules linking`death receptors' from the TNF-R/CD95 family to the apoptotic machinery during the initiation phase of apoptosis, in other pathways, namely those mediated by Bax, Bak, p53, ceramide, glucocorticoid receptors, or CD45, they are dispensable for the activation of mitochondrial changes and rather participate in the degradation phase (DeMaria et al., 1997; Hirsch et al., 1997; Lesage et al., 1997; McCarthy et al., 1997; Xiang et al., 1996) . This implies that the disruption of mitochondrial membrane function is by itself sucient to cause cell death, via apoptosis or necrosis (that is cell death without the morphological signs of apoptosis), and that, at least at the postmitochondrial level, caspase activation decides the , among others) converge on mitochondria. Note that in some special cases mitochondria can participate iǹ private' pathways, e.g. by producing ROS in response to ceramide (Quillet-Mary et al., 1997) Eector (mitochondrial) Mitochondrial membrane function is perturbed at the levels of the inner membrane (disruption of the DC m ) and/or the outer membrane causing the release of intermembrane proteins into the cytosol. The bioenergetic consequences of these changes (cessation of anti-oxidant functions and ATP generation) and/ or the activation of caspases by intermembrane proteins engage in a feedback ampli®cation loop further compromising mitochondrial membrane function.
Degradation (post-mitochondrial) Major changes in cellular physiology at all levels . plasma membrane: exposure of phosphatidylserine residues, out¯ow of K + , later in¯ux of Ca +2 , increase in permeability, and ®nally cytolysis . redox protentials: depletion of non-oxidized glutathione, hyperproduction of reactive oxygen species, oxidation of unsaturated lipids and mitochondrial cardiolipin . caspases: activation of the caspase cascade and degradation of multiple structural and repair proteins in the cytosol, cytoskeleton, and nucleus . non-caspase proteases: activation of calpains and other proteases . nucleases: step-wise chromatin degradation Bcl-2-like oncoproteins N Zamzami et al mode of cell death rather than its advent. After dissipation of the DC m and/or release of cytochrome c (which disrupts the transfer of electrons between respiratory chain complexes III and IV), mitochondria lose their anti-oxidant function, produce superoxide anion, and provoke a bioenergetic catastrophe, culminating in cell death irrespective of the activation of caspases and endonucleases (DeMaria et al., 1997; Hirsch et al., 1997; McCarthy et al., 1997; Xiang et al., 1996) . In some models of receptor-mediated apoptosis, caspase and nuclease activation does not occur, although cell death is preceded by DC m disruption (Lavoie et al., 1998; Lesage et al., 1997) . In general terms, it appears that DC m disruption has a higher predictive value for cell death than caspase or endonuclease activation. Thus, cells with an altered DC m are irreversibly committed to death (Brunet et al., 1998; Hirsch et al., 1997; Xiang et al., 1996; Zamzami et al., 1995b) , whereas caspase activation can occur without cell death (Boise and Miossec et al., 1997) . These two notions, namely that (i) mitochondria play an important role in the life/death decision and that (ii) caspases constitute, at best, only part of the central executioner are of obvious importance for the comprehension of cytoprotective eects mediated by Bcl-2 related proteins.
Biological eects of bcl-2-related proteins in vivo
Transgenic animals overexpressing Bcl-2-related proteins Transgene-enforced overexpression of members of the Bcl-2 family under the control of dierent promoters has revealed the striking capacity of Bcl-2 and Bcl-X L to confer apoptosis resistance to a number of dierent tissues including lymphocytes (McDonnell et al., 1989; Sentman et al., 1991; Strasser et al., 1991) , spermatogonia (Furuchi et al., 1996) , ovary follicles (Hsu et al., 1996) , neurons , hepatocytes (Lacronique et al., 1996) , retinal photoreceptors , mammary parenchyma (Jager et al., 1997) , prostate epithelium (Zhang et al., 1997) , keratinocytes (Pena et al., 1997) , or lens cells (Fromm and Overbeek, 1997) . Overexpression of Bcl-2 in lymphoid cells can cause the development of lymphomas. However, lymphomas only develop at an advanced age in an oligoclonal fashion, suggesting that additional mutations in (anti-) oncogenes have to occur to allow for tumor development (Cory, 1995) . Accordingly, the simultaneously expression of other oncogenes such as c-myc substantially accelerates the development of lymphomas (Strasser et al., 1990 (Strasser et al., , 1996 and mammary tumors induced by Bcl-2 expression (Jager et al., 1997) . The cytoprotective eect of Bcl-2 and Bcl-X L is rather broad. However, this eect is not absolute. Both Bcl-2 and Bcl-X L largely fail to prevent the clonal deletion of self-reactive thymocytes, conventional B cells, and peripheral T cells in vivo (Sentman et al., 1991; Strasser et al., 1991) . Expression of proapoptotic members of the Bcl-2 family sensitizes cells for apoptosis induction. Thus, transgenic expression of Bcl-X S reduces the resistance of keratinocytes to UV irradiation (Pena et al., 1997) , whereas a Bax transgene accelerates thymocyte apoptosis induced by glucocorticoid, g-irradiation, and topoisomerase inhibition (Brady et al., 1996) .
Knock-out studies
Homologous recombination (Table 2) revealed that Bcl-2 de®ciency is deleterious for certain cell types including lymphocytes (Nakayama et al., 1994) , melanocytes (Yamamura et al., 1996) , intestinal epithelial cells (Kamada et al., 1995) , and some classes of neurons (Michaelidis et al., 1996) . De®ciency of Bcl-X causes intrauterine death accompanied by massive loss of postmitotic immature neurons (Motoyama et al., 1995) . Lymphocytes from such mice have a shortened life-span (Motoyama et al., 1995) . The knock-out of Bax causes hyperplasia of lymphocytes, premeiotic germ cells (Knudson et al., 1995) , and some classes of neurons (Deckwerth et al., 1996) . Bax de®ciency causes accelerated proliferation of a transgenic brain tumor , indicating that Bax functions as a tumor suppressor gene. Bax
7/7
Bcl-X 7/7 do not manifest the increased cell death of immature neurons observed in Bax +/+ Bcl-X 7/7 mice (Shindler et al., 1997) . Similarly, the thymic hypoplasia characteristic of Bcl-2 7/7 mice is largely absent in mice also de®cient in Bax , underlining the importance of an equilibrium between pro-apoptotic (Bax) and anti-apoptotic (Bcl-2, Bcl-X L ) proteins for the regulation of cell survival. Whereas such proteins have no eect on cellular dierentiation, they can aect the cell cycle of selected cell types (Table 2) .
A wide but limited range of anti-apoptotic action
The eect of Bcl-2 on cellular physiology has been studied in multiple Bcl-2-transfected cell lines, in which it enhances the resistance to cell death induced by most but not all stimuli. It appears that Bcl-2 and other cytoprotective members of the Bcl-2 family have roughly the same spectrum of action (although quantitative dierences in their ecacy may exist (Simonian et al., 1997) ), suggesting that they ful®l similar functions in the cell. Bcl-2 and its homologs prevent cell death induced by a plethora of dierent stimuli. This includes apoptosis induced via the p53-dependent pathway, ceramide, glucocorticoids, chemotherapy, and growth factor withdrawal. Bcl-2 also inhibits necrosis induced by chemical hypoxia (sodium azide (Strasser et al., 1991) ; cyanide, rotenone, antimycin A (Shimizu et al., 1996b) , kainic acid (Kane et al., 1993) and TNF-a (in mouse L929 cells) (Albrecht et al., 1994) . Thus, the cytoprotective eects of Bcl-2 extend to most cases of apoptosis and some cases of necrosis. In contrast, Bcl-2 fails to prevent apoptosis induced by microinjection of caspases . Accordingly, Bcl-2, Bcl-X L , Bcl-w, and E1B19K are largely ineective in preventing apoptosis induced via crosslinking of CD95-like receptors (CD95/Fas/Apo-1, TRAMP) causing a primary caspase activation (Bodmer et al., 1997; Huang et al., 1997a; Susin et al., 1997) , but some protection has been reported in some cell lines . Although Bcl-2 confers resistance to most xenobiotics, it has no eect on apoptosis induced by the thiol-crosslinking agent diazenedicarboxylic acid bis 5N,N-dimethylamide (diamide) and the microtubule-disrupting agents taxol, taxotere, vinblastine, and vincristine (Blagosklonny et al., 1997; Haldar et al., 1997) .
Pleiotropic eects on cellular physiology
Bcl-2 overexpression prevents all changes in cellular physiology commonly associated with apoptosis, including mitochondrial changes, activation of caspases and nucleases, loss of plasma membrane asymmetry, redistribution of ions (Ca 2+ , K + , protons) and oxidative changes in the cellular redox balance (Table 3 ). The cause eect relationship between these changes has been unraveled in cell-free systems and will be discussed below. Bcl-2 also aects some cellular functions not directly linked to apoptosis, such as G 0/1 ?S transition. Retention of the p53 protein in the cytoplasm caused by Bcl-2 overexpression Ryan et al., 1994 ) is unlikely to be the principal mechanism of apoptosis inhibition, because Bcl-2 prevents apoptosis in p53 7/7 cells (Strasser et al., 1994) . Some authors have suggested that Bcl-2 may shift the steady state redox balance to a more reduced state (Ellerby et al., 1996) , enhance the DC m (Hennet et al., 1993) or increase baseline ATP generation (Smets et al., 1994) . However, these eects are only found in some cell lines and thus cannot explain the general cytoprotective eect of Bcl-2.
In conclusion, the main biological eect of Bcl-2 and its analogs is cytoprotection. Cytoprotection implies the prevention of all hallmarks of apoptosis, including the mitochondrial changes and post-mitochondrial caspase activation. However, Bcl-2 is (relatively) inecient when caspases are activated directly, and in that case it fails to prevent the disruption of mitochondrial membrane function .
Interactions among members of the BCL-2 family: who makes the death/life decision?
Bcl-2 homology regions
The ratio of death antagonists (Bcl-2, Bcl-X L , Bcl-w, Mcl-1, A1/B¯-1) or agonists (Bax, Bak, Bcl-X S , Bad, Bid, Bik, Bim, Bok, Hrk) in¯uences the susceptibility of cells to apoptosis. This death/life rheostat is mediated, at least in part, by competitive dimerization between selective pairs of antagonists and agonists (Sedlak et al., 1995) . Since each of the members of the Bcl-2 family is expressed in a cell type-, dierentiation-, and activation stage-speci®c fashion, a network of pairs of interacting proteins (e.g. Bcl-2/Bax, Bcl-X L /Bak, Mcl-1/Bok etc.) in¯uences cell fate. Sequence comparisons and mutational analysis have revealed the existence of up to four Bcl-2 homology (BH) domains (Figure 1 ). All anti-apoptotic and several among the pro-apoptotic members of the Bcl-2 family (Bax, Bak, Bok) possess three such domains: BH1, BH2 and BH3, which are involved in the formation of homodimers and heterodimers among members of the Bcl-2 family. A fourth BH domain (BH4), the most N-terminal one, is only found among death antagonists and is involved in the interaction with proteins not belonging to the Bcl-2 family such as Bag-1 and Raf-1. Several among the death antagonists only possess a BH3 domain (Bad, Bid, Bim, Hrk) and thus form the`BH3 only' branch of the Bcl-2 family (Figure 1 ). Although proteins of the Bcl-2 family contain BH3 domains, sequence dierences clearly distinguish the BH3 domain of the anti-and pro-apoptotic members of the family. Thus, a swap of a 23 aminoacid segment surrounding BH3 from Bax into Bcl-2 converted Bcl-2 from a death antagonist to a death agonist . (Nakayama et al., 1994 ) Lymphopenia (Nakayama et al., 1994 ) Accelerated G1-S cell cycle progression in T cells (Linette et al., 1996) Multicystic kidney, renal hypoplasia and renal failure (Nakayama et al., 1994; Sorenson et al., 1996) Gray hair due to accelerated loss of melanocytes (Yamamura et al., 1996) Decrease in the number of oocytes and primordial follicles (Ratts et al., 1995) Distorted small intestine with accelerated exfoliation of epithelial cells (Kamada et al., 1995) Degeneration of motoneurons, sympathetic, and sensory neurons during early postnatal development (Michaelidis et al., 1996) Enhanced susceptibility of cerebellar granule neurons to undergo apoptosis in vitro (Tanabe et al., 1997) Reduced axon growth rate in embryonic sensory neurons culutured in vitro (Hilton et al., 1997) Bcl-X Intrauterine death (E13) (Motoyama et al., 1995) Massive death of postmitotic immature neurons (Motoyama et al., 1995) Shortened life-span of immature lymphocytes (Motoyama et al., 1995) Enhanced death of serum-depleted telencephalic cells in vitro Bxl-w Sterility with progressive testicular degeneration, blockade in late spermiogenesis (Ross et al., 1998) (Deckwerth et al., 1996) More neurons in cervical ganglia and facial nuclei (Deckwerth et al., 1996) Prevents increased cell death of immature neurons in Bcl-X 7/7 mice (Shindler et al., 1997) Asymmetric receptor/ligand interactions among members of the Bcl-2 family Mutagenesis studies and NMR data revealed that intact BH1, BH2 and BH3 domains of the antagonists (Bcl-2, Bcl-X L ) are required for them to heterodimerize with the BH3 domain of Bak or Bax and to repress cell death (Sattler et al., 1997; Sedlak et al., 1995; Ying et al., 1994) . It appears that the BH3 region forms and a helix which nestles into a crevice formed by the apposition of the BH1, BH2 and BH3 regions (Sattler et al., 1997) . The BH3`ligand' domain thus binds to the`receptor' formed by the combination of BH1, BH2 and BH3. This implies an asymmetry in the formation of homo-and heterodimers in which one partner functions as receptor and the other as a ligand. BH3 peptides disrupt dimerization among dierent members of the Bcl-2 family (Bcl-2/Bcl-2, Bcl-2/Bax, Bax/Bax) (Diaz et al., 1997), indicating that similar binding motifs are responsible for both homodimerization and heterodimerization of Bcl-2 family members. In many cases, disruption of the BH1, BH2 and/or BH3 structures by mutation or deletion yields molecules that have reduced their pro-or anti-apoptotic capacity, respectively
Autonomous functions of death antagonists and agonists
A long-standing problem is which among these structures are the active ones: (i) homodimers or heterodimers that are composed of death antagonists (e.g. Bcl-2/Bcl-2, Bcl-2/Bcl-X L ), which would actively inhibit death; (ii) dimers of death agonists (e.g. Bax/ Bax), which would actively trigger the apoptotic cascade; or (iii) mixed dimers of death agonists plus antagonists, which would regulate apoptosis (e.g. Bcl-2/Bax, Bcl-X L /Bax). This question has been dicult to address because mammalian cells generally express Table 3 Biological eects of Bcl-2 on intact cells
Group of eects Observation References
Cell cyle eects Retards G0/1→S transition (Borner, 1996; Linette et al., 1996; Mazel et al., 1996) Hyperphosphorylation of Rb (Wang et al., 1996a ) Retains p53 in the cytoplasm during G 1 phase (Ryan et al., 1994 ) Inhibition of nuclear translocation of NFAT (Linette et al., 1996) Plasma membrane eects Prevents phosphatidylserine exposure (Martin et al., 1995b ) Prevents recognition by phagocytic cells (Flora et al., 1996) Eects on redox potentials Decreased lipid peroxidation (Hockenbery et al., 1993 ) Inhibition of ROS generation (Kane et al., 1993) Increase in catalase and superoxide dismutase in some cell lines (Ellerby et al., 1996) Decreased baseline hydroxyl radical production (Wiedaupazos et al., 1996) Increase in total GSH and in non-oxidized GSH (Ellerby et al., 1996; Heldy and Mcculloch, 1996 ) Elevated NAD + NADH ratio (Ellerby et al., 1996) Inhibition of apoptosis-associated glutathione depletion (Ellerby et al., 1996; Hedley and Mcculloc, 1996; Macho et al., 1997) Eects on NFkB Restores the Fas-induced NFkB (p50/relA) signaling pathway (Mandal et al., 1996) Inhibition of the transactivating potential of NF-kB p65 (Grimm et al., 1996) Eects on kinases Prevents activation of JNK1 by ceramide Eect on CED4 Retains CED4 in intracellular membranes, thus hindering it from acting on the nucleus (Chinnaiyan et al., 1997; Wu et al., 1997) Eects on proteases Inhibition of caspase activation and cleavage of nuclear substrates such as PARP (Armstrong et al., 1996; Boulakia et al., 1996; Chinnaiyan et al., 1996; Shimizu et al., 1996a) Eects on intracellular ions Prevention of cytoplasmic acidi®cation (Meisenholder et al., 1996; Reynolds et al., 1996) Prevention of H 2 O 2 -induced calcium in¯ux (ZoÈ rnig et al., 1995) Inhibition of hydrogen peroxide-or thapsigargin-induced Ca 2+ out¯ow from the ER (He et al., 1997; Lam et al., 1994) Preservation of the ER Ca 2+ pool in cells cultured in low extracellular Ca 2+ (He et al., 1997) Inhibition of Ca 2+ uptake into the nucleus (Marin et al., 1996) Prevents K + loss during late apoptosis Eects on mitochondria Inhibition of pre-apoptotic DC m disruption in many cell types (Kroemer et al., 1995) Enhanced steady-state DC m in some cell lines (Hennet et al., 1993) Increase in ATP generation in some cell lines (Smets et al., 1994) Increases the maximum Ca 2+ retention compatible with NADHdependent respiration in neurons Prevents in¯ux of calcium into mitochondria induced by growth factor withdrawal (Bay et al., 1993) Prevents out¯ow of cytochrome c from the intermembrane space (Kluck et al., 1997a; Yang et al., 1997 ) Prevents oxidation of cardiolipin molecules (Zamzami et al., 1995a ) Prevents generation of ROS in mitrochondria Zamzami et al., 1995a) several members of the Bcl-2 family at the same time, and overexpression of mutated Bcl-2-like proteins thus can simultaneously aect several endogenous death agonists and death antagonists. Transfection of yeast cells (Saccharomyces cerevisiae or Schizosaccharomyces pombe), whose entire genome is sequenced and lacks Bcl-2-like proteins, has shown that Bax and Bak clearly have a killer activity which can be neutralized by simultaneous expression of Bcl-2 or Bcl-X L (Table 4 ) (Ink et al., 1997; Jurgensmeier et al., 1997; Manon et al., 1997; Sato et al., 1994; Torgler et al., 1997; Zha et al., 1996a) . Physical interaction between Bcl-2 and Bax is not required for the Bcl-2-mediated inhibition of Bax-induced apoptosis (Zha and Reed, 1997) . Expression of Bcl-2 alone also has an eect. It rescues yeast cells from death induced by superoxide dismutase de®ciency and enhances survival in conditions of starvation (Kane et al., 1993; Longo et al., 1997 .
In conclusion, it appears that members of the Bcl-2 family interact among each other to form a dynamic equilibrium between homo-and heterodimers. While an in vivo competition exists between pro-apoptotic and anti-apoptotic members of the Bcl-2 family, at least some of the pro-apoptotic and anti-apoptotic proteins regulate apoptosis independently. The exact stoichiometry of these reactions (dimers, tetramers etc.?) has not been elucidated, and it remains possible that Bcl-2-like proteins form part of a higher order multiprotein complex involving additional proteins not belonging to the Bcl-2 family.
Subcellualr localization of Bcl-2 and its homologs

Predominant localization to intracellular membranes
As discussed above (Table 3) , Bcl-2 prevents the manifestations of apoptosis at the levels of the nucleus, the mitochondrion, the plasma membrane, and the cytosol. But where and how does it exert this pleiotropic action? With few exceptions (E1B19K, A1, Bad, Bid), the proteins of the Bcl-2 family possess a Cterminal *20-residue hydrophobic transmembrane (TM) domain (Figure 1 ) which determines their insertion into dierent intracellular membranes including those of the endoplasmic reticulum, the nuclear envelope, and mitochondrial membranes. The intracel- Figure 1 Domain structure of members of the Bcl-2 family. The gross protein domain structure is indicated for dierent members of the Bcl-2 family (not drawn to scale). Note that certain Bcl-2 homology regions (BH1 through BH4, in solid) or C-terminal hydrophobic membrane insertion sequences (tinted) are missing in determined members of the family. Some structural features (a domains) and functions determined by cristallographic or mutational analysis are indicated (Longo et al., 1997) Bcl-X L ; Mcl-1; A1 Prevent Bax/Bak-mediated killing (Manon et al., 1997; Sato et al., 1994; Tao et al., 1997) S. Pombe Bax Cell killing with chromatin condensation and vacuolization (Jurgensmeier et al., 1997) Bak Slow growth phenotype and killing with chromatic condensation and lamin dissolution (Ink et al., 1997; Jurgensmeier et al., 1997; Torgler et al., 1997) Bcl-X L , Bcl-2 Prevent Bax/Bak-mediated eects (Jurgensmeier et al., 1997; Ink et al., 1997; Torgler et al., 1997) CED-4 Causes chromatin condenstaion and death CED-9 Prevents CED-4-induced death lular distribution of dierent members of the Bcl-2 family can depend on the cell type as well as on the family member. Thus, Bcl-2, Bcl-X L , Bax, and the Epstein ± Barr virus gene product BHRF tend to be particularly abundant in the outer mitochondrial membrane (Cory, 1995; Gonzalez-Garcia et al., 1994; Krajewski et al., 1993; Reed, 1994; Riparbelli et al., 1995; Yang and Korsmeyer, 1996; Zha et al., 1996a) . In contrast, E1B19K, which lacks a TM domain, is mostly localized in the nuclear envelope (Rao et al., 1997 ). It appears unlikely that mere TM-lipid interactions determine the subcellular localization of these proteins. The preferential localization of E1B19K may be dictated by protein-protein interactions with nuclear lamins A/C (Rao et al., 1997) , whereas, in the case of Bcl-2, interactions with mitochondrial outer membrane proteins (perhaps carnitine palmitoyltransferase I?) (Paumen et al., 1997) may be important. In the mitochondrion, Bcl-2 is not distributed in a diuse fashion but rather demonstrates a patchy distribution to the contact sites between the outer and the inner mitochondrial membrane (Krajewski et al., 1993; Riparbelli et al., 1995) .
The impact of mitochondria
Upon deletion of the TM domain, most of the Bcl-2 (Bcl-2DTM) is retained in the cytosol, although some protein may associate with membranes, perhaps a consequence of interactions with other Bcl-2 family members (Sedlak et al., 1995) . This manipulation abrogates (Alnemri et al., 1992; Nguyen et al., 1994; Tanaka et al., 1993) or diminishes (Hockenbery et al., 1993; the death-inhibitory eects of Bcl-2, depending on the experimental system ( (Zha et al., 1996a) . Yeast cells with mutations in nuclear genes coding for the mitochondrial F 0 F 1 ATPase are resistant to the lethal eect of Bax (Matsuyama et al., 1998) , a ®nding which underlines the functional impact of Bax on mitochondria. Again, only mitochondrion-targeted Bcl-X L , Bcl-2, or Mas70-Bcl-2 fusion proteins (but not Bcl-2DTM) are able to antagonize the lethal eect of Bax (Greenhalf et al., 1996; Zha et al., 1996a) . In addition, Bcl-2 and Bcl-X L can determine the subcellular localization of apoptosis regulators with whom they interact. Thus, Bcl-2 can target the protein kinase Raf-1 to mitochondria (Wang et al., 1996b) , and Bcl-X L can retain the C. elegans deathregulatory proteins Ced-4 (and presumably its mammalian homolog Apaf-1) in intracellular membranes, thereby hindering it from entering the nucleus and exerting its pro-apoptotic activity (Chinnaiyan et al., 1997; Wu et al., 1997) . It is possible that, via Apaf-1, Bcl-2 can also complex certain caspases (e.g. caspase 9) to the mitochondrion, thereby sequestering them from their site of action (Chinnaiyan et al., 1997) . The apoptosis-inhibitory potential of Bcl-2 remains intact when it is speci®cally targeted to mitochondrial membranes by exchanging the carboxyterminal insertion sequence for an equivalent sequence from ActA or from the yeast outer mitochondrial membrane protein Mas70 (Table 5 ) (Nguyen et al., 1994; Zhu et al., 1996) .
Putative role of the endoplasmic reticulum
As discussed above, most studies suggest that Bcl-2-related proteins have to localize to mitochondria to regulate apoptosis. However, in some experimental systems Bcl-2 is also active when speci®cally targeted to the ER (and the outer membrane of the nuclear envelope, which is topologically equivalent to the ER membrane) using the cytochrome B5 insertion sequence (Table 5 ) (Zhu et al., 1996) . This may mean that Bcl-2 exerts some of its eects on other organelles than mitochondria or, alternatively, neutralizes pro-apoptotic Bcl-2-related proteins, thereby hindering them from acting on mitochondria. Indeed, ER-targeted Bcl-2 has (Zhu et al., 1996) (Zhu et al., 1996) been shown to interact with Bax (Zhu et al., 1996) , which in turn must act on mitochondria to kill cells (Zha et al., 1996a) . Moreover, whenever ER-targeted Bcl-2 succeeds in preventing nuclear apoptosis, it also stabilizes mitochondrial membrane function (Figure 2 ). Bcl-2 can also interact with the ER membrane protein p28Bap31, which in turn associates with caspase-8 . Some observations suggest that Bcl-2 exerts local functions on the endoplasmatic reticulum. Thus, in intact cells, Bcl-2 reduces the Ca 2+ out¯ow from the ER induced by H 2 O 2 or thapsigargin (Distelhorst et al., 1996; He et al., 1997) . It remains to be clari®ed whether this eect is due to the local presence of Bcl-2 or whether Bcl-2 can act on the ER in trans, via its eect on other organelles. ER-targeted Bcl-2 inhibits apoptosis induced by some stimuli, for instance c-myc overexpression and serum withdrawal (Zhu et al., 1996) , yet fails to prevent apoptosis induced by tert-butylhydroperoxide, or etoposide. In contrast, mitochondria-targeted Bcl-2 is an ecient inhibitor of apoptosis induced by all these stimuli (unpublished, Figure 2 ). This suggests that Bcl-2 is a more ecient inhibitor of apoptosis when localized to mitochondria rather than in ER.
Eects on the nucleus
Bcl-2 has been suggested to modulate apoptosis by aecting the nuclear translocation of transcription factors such as p53 Ryan et al., 1994) and NFAT (`nuclear factor of activated T cells') (Linette et al., 1996) . However, the functional impact of these eects on apoptosis regulation is controversial, since Bcl-2 protects against both p53-dependent and p53-independent cell death. The eect on NFAT translocation (which only would aect T cells, i.e. the cell type expressing this transcription factor) has been related with Bcl-2's eect on the cell cycle (Linette et al., 1996) , which can be dissociated from its antiapoptotic eect (Huang et al., 1997b) . Bcl-2 has also been shown to increase the concentration of glutathione (GSH) in the nucleus (Voehringer et al., 1998) and to reduce the Ca 2+ uptake into isolated nuclei (Marin et al., 1996) . However, Bcl-2 can protect cytoplasts (that is anucleate cells) against apoptosis Decaudin et al., 1997; Jacobson et al., 1994) . In the case of E1B19K, nevertheless, evidence is available suggesting that this protein loses its anti-apoptotic eect when it is targeted to an extranuclear localization by overexpressing mutants of lamin A/C which localize inappropriately to the cytoplasm (Rao et al., 1997) . In summary, the nuclear localization of Bcl-2-related proteins can have some impact on speci®c (private) pathways of apoptotic signaling, yet is unlikely to account for the broad cytoprotective eect of Bcl-2.
Redistribution of Bcl-2-like proteins
Complicating the search for the actual site of action of Bcl-2, recent evidence suggests that the subcellular localization of at least certain members of the Bcl-2 family changes during apoptosis. Thus, Bax and Bcl-X L but not Bcl-2 have been found to redistribute from the cytosol to intracellular membranes upon induction of thymocyte apoptosis (Hsu et al., 1997) . The proapoptotic protein Bad, which lacks a TM domain, is another protein which redistributes in response to some inducers of apoptosis. Upon serine phosphorylation by the serine/threonine kinase Akt (and other unrelated kinases), Bad binds to the cytosolic phosphoserinebinding protein 14-3-3 (Datta et al., 1997; del Peso et al., 1997; Zha et al., 1996b) and thereby relocalizes from the mitochondrion, where it neutralizes Bcl-2-like proteins, to a site at which it has no biological eects. Akt is activated by other kinases such as PDK1 (phosphoinositide-dependent kinase-1), phosphoinositol-3,4-bisphosphate, and phosphoinositol-3,4,5-trisphosphate. Thus, signal transduction involving phosphoinositol derivatives and kinases can regulate the subcellular distribution of Bad. It remains to be determined which other members of the Bcl-2 family relocalize in the cell during apoptosis induction. Moreover, it is still unknown whether members of the Bcl-2 famility can translocate, within the inner/ outer contact site, from the inner to the outer mitochondrial membrane.
In summary, all data obtained with yeast cells and most results obtained in the mammalian system suggest that the primordial site of action of Bcl-2-like proteins is the mitochondrion. However, additional extramitochondrial sites of action may exist.
Bcl-2 eects on isolated organelles
Cell free systems recapitulate apoptosis in three steps
Cell-free systems of apoptosis combine puri®ed organelles (cytosol, mitochondria, nuclei) with the aim of recapitulating essential steps of the apoptotic process. Most data are compatible with a three-step model. At the pre-mitochondrial initiation step, cytosolic factors accumulate after pro-apoptotic signaling. These factors include Ca 2+ , reactive oxygen species, nitric oxide, upstream caspases, and Bax which all can act on mitochondria to disrupt the function of the inner and/ or outer mitochondrial membranes. During the Figure 2 Anti-apoptotic eects of Bcl-2 targeted to the mitochondrion or to the ER. Bcl-2 (symbolized as black spots) was targeted either to the mitochondrion (actA-Bcl-2 fusion protein) or to the ER and the nuclear envelope (cb5-Bcl-2) fusion protein in Rat/myc cells (Table 5) (Zhu et al., 1996 . Bcl-2 present in mitochondria has a wider ranger of anti-apoptotic action than Bcl-2 targeted to the ER. In all cases in which Bcl-2 succeeds in preventing nuclear apoptosis, it also abrogates the DC m disruption preceding DNA fragmentation Bcl-2-like oncoproteins N Zamzami et al mitochondrial eector/decision step, major alterations in mitochondrial membrane function occur. These changes include the permeability transition (PT), that is disruption of the DC m due to opening of the mitochondrial megachannel and/or the release of caspase-and nuclease-activating factors via the outer mitochondrial membrane. During the post-mitochondrial degradation stage, mitochondrial supernatants cause the proteolytic activation of recombinant procaspases and of nucleases. The hydrolase-activating factors contained in such supernatants include cytochrome c and the`apoptosis-inducing factor' (AIF) (Kluck et al., 1997a,b; Liu et al., 1996; Martin et al., 1995a; Newmeyer et al., 1994; Susin et al., 1996 Susin et al., , 1997 Yang et al., 1997; Zamzami et al., 1996b) .
Eects of Bcl-2 and Bax on isolated mitochondria
Bcl-2 overexpression augments the resistance of mitochondria to undergo PT in response to a number of dierent agents, including atractyloside, a substance that speci®cally aects the adenine nucleotide translocator of the inner mitochondrial membrane. Bcl-2 also prevents DC m disruption induced by tert-butylhydroperoxide and low doses of calcium Zamzami et al., 1996b) . However, as to be expected, it fails to protect isolated mitochondria against recombinant caspases or diamide Zamzami et al., 1996b) . In addition to its DC m stabilizing eect, Bcl-2 causes the retention of apoptosis-inducing factors (AIF) in the intermembrane space of mitochondria, suggesting that it maintains the integrity of the outer membrane. Bcl-2 overexpressing mitochondria retain AIF activity in all cases in which Bcl-2 prevents PT . Bcl-2 also inhibits the liberation of cytochrome c induced by cytosols of dying frog oocytes (Kluck et al., 1997a) , mild osmotic shock and the amphipathic peptide reaper (Evans et al., 1997) . Thus, Bcl-2 stabilizes both the inner and the outer mitochondrial membranes. Recent data obtained with isolated mitochondria indicate that recombinant Bax protein can induce both DC m dissipation and cytochrome c release. This ®nding has been con®rmed in mammalian and yeast cells transfected with Bax (Manon et al., 1997; RosseÂ et al., 1998; Xiang et al., 1996) , suggesting that Bax acts to destabilize mitochondrial membrane function.
Putative nuclear eects of Bcl-2
The local presence of Bcl-2 in isolated nuclei fails to prevent signs of nuclear apoptosis (nuclear chromatin condensation, DNA fragmentation) induced by mitochondrial supernatants. Moreover, recombinant Bcl-2 fails to prevent the activation of pro-caspases and nucleases by mitochondrial supernatants in vitro (Kluck et al., 1997a; Susin et al., 1996 Susin et al., , 1997 Zamzami et al., 1996b) , indicating that Bcl-2 does not aect the apoptotic degradation phase. It has been reported that Bcl-2 present in the nuclear envelope can prevent the ATP-facilitated Ca 2+ in¯ux into isolated nuclei (Marin et al., 1996) and increase the accumulation of radiolabeled glutathione into isolated nuclei (Voehringer et al., 1998) . It has also been shown to suppress granzyme B-and Ca 2+ -induced nuclear DNA fragmentation induced in vitro (Mcconkey, 1996; Voehringer et al., 1998) . However, it is unclear whether these eects are related to the apoptosis-inhibitory eect of Bcl-2, because massive calcium increases occur well after DC m disruption, when cells are already in an irreversible stage of apoptosis . Moreover, endonuclease activation does not require Ca 2+ in most cell-free systems (Martin et al., 1995a; Newmeyer et al., 1994; Susin et al., 1996; Zamzami et al., 1996b) , shedding again doubts against a role of Ca 2+ as a universal death eector. Finally, Bcl-2 can retard staurosporineor ceramide-induced death in anucleate cells Decaudin et al., 1997; Jacobson et al., 1994) , indicating that its nuclear localization is dispensable for its function, in accord with the results obtained by directing Bcl-2 fusion proteins to distinct subcellular compartments (Figure 2 , Table 5 ).
Pore function of Bcl-2-like proeins in arti®cial membranes
The dual structure of Bcl-2-like proteins
The Bcl-X L structure bears a striking resemblance to that of several pore-forming proteins. In particular it resembles the translocation domain of diphteria toxin and the pore-forming domains of colicins A and E (Muchmore et al., 1996) . Each of these toxins possesses a hydrophobic`dagger' is shielded within a shell of amphipathic a helices, allowing them to exist either in a soluble stage or insert into membranes to form a channel. Two a helices of Bcl-X L (a5 and a6) are suciently long to span the membrane bilayer and thus may participate in channel formation, although, on their own, within the Bcl-X L monomer, they are insucient to enclose an aqueous lumen. It may be speculated that Bcl-2-like proteins ®rst insert into membranes via their TM domain while conserving an overall globular structure, and then insert thè dagger' (a5 and a6) which, when they are included into Bcl-2 dimers or higher-order structures, can form eective pores. The globular structure, with closely juxtaposed BH1, BH2, and BH3 (and BH4) domains, could act as the`receptor' during homo-and heterodimerization. In contrast, the`dagger' structure would imply unfolding of the globular structure leading to the liberation of the BH3 domain which can act as the`ligand' (Reed, 1997) . If this was the case, asymmetric receptor/ligand interactions between members of the Bcl-2 family would dictate their propensity to form pores. Since the`dagger' structure also liberates the BH3 and BH4 domains, interactions mediated via BH3/BH4 could also regulate pore formation.
Channel properties of Bcl-2 homologs in vitro
In vitro channel formation by recombinant Bcl-X L , Bcl-2, and Bax incorporated into arti®cial membranes has been studied in detail Schendel et al., 1997; Schlesinger et al., 1997) (Table 5) . Recombinant Bcl-X L and Bcl-2 lacking the TM domains only form channels when they are incorporated into membranes containing 30 ± 40%
Bcl-2-like oncoproteins N Zamzami et al acidic lipids. Pore formation is only observed at an unphysiologically low pH (pH 4.0 or 5.5 for Bcl-X L and Bcl-2, respectively), suggesting that protonation of these proteins facilitates incorporation into lipid membranes and/or pore formation. The channels formed by Bcl-X L and Bcl-2 have several levels of conductance (80, 134, 179 , 276 pS of Bcl-X L ; 20, 40, 90 pS and up to 1.9 nS for Bcl-2) and mild K + selectivity Schendel et al., 1997; Schlesinger et al., 1997) . In contrast, Bax demonstrates a larger pH range of activity, incorporates into membranes containing neutral lipids, and demonstrates mild Cl 7 selectivity. Its conductance may raise at neutral pH from values of 26, 80, 180 and 250 pS to maximum levels of 1.5 ± 2 nS Schlesinger et al., 1997) . In this context it appears intriguing that contact sites of mitochondria contain a variety of channels, some in the 10 ± 80 pS range, others conducting at 475 and 550 pS (Moran and Sorgato, 1992 ) and up to a maximum of 2 nS (Kinnally et al., 1996) . It thus appears plausible that Bax (and other members of the Bcl-2 family?) participate in the formation and/or regulation of the mitochondrial`multiple conductance channel' (Kinnally et al., 1996) .
Who forms channels in vivo?
Do the in vitro experiments imply that both death agonists and death antagonists from pores in natural membranes? Recent experiments suggest than only Bax and not Bcl-2 forms a pore. Pre-incubation of Bax with a tenfold excess of Bcl-2, prior to incorporation into liposomes, prevents its channel activity at neutral pH . This would suggest that Bax can form a pore, whereas Bcl-2 normally (at normal pH) would not form a pore and rather prevent Bax from doing so. As a possibility, Bcl-2 might heterodimerize with Bax, thereby hindering it from undergoing the transition from the globular to the membrane-inserted state or vice versa (Reed, 1997) . Based on secondary structure predictions, it appears unlikely that the`BH3-only' branch of the Bcl-2 family (Bik, Bad, Bak, Hrk, Nip-3) will form channels. If the channel function of Bax and the channel-inhibitory eects of Bcl-2/Bcl-X L were decisive for apoptosis regulation, it therefore appears plausible that the`BH3-only' branch acts as transdominant inhibitor of anti-apoptotic proteins such as Bcl-2 and Bcl-X L .
The permeability transition pore complex: impact of Bcl-2-like proteins
The permeability transition pore complex in apoptosis Pharmacological and functional studies indicate that the DC m collapse occurring during early apoptosis is due to the opening of the mitochondrial permeability transition (PT) pores rather than due to non-speci®c damage of mitochondria Zamzami et al., 1995a Zamzami et al., , 1996a . The PT pore participates in the regulation of matrix Ca 2+ , pH, DC m , and volume and functions as a Ca 2+ -, voltage-, pH-, and redox-gated channel with several levels of conductance and little if any ion selectivity (Bernardi and Petronilli, 1996; Ichas et al., 1997; Zoratti and SzaboÁ , 1995) . PT pores are multiprotein complexes formed at the contact site between the mitochondrial inner and outer membranes, exactly at the same localization at which Bax, Bcl-2 and Bcl-X L are particularly abundant. Their opening/closing characteristics is in¯uenced by multiple parameters: voltage (high voltage inhibits), the redox state of critical matrix thiols (reduction of thiols inhibits), the NAD(P)H 2 / NAD(P) ratio (reduction inhibits), the matrix pH (low pH inhibits), the concentration of Ca 2+ and other divalent cations (matrix Ca 2+ opens but Mg 2+ closes), and the concentrations of ligands of hexokinase (glucose inhibits), creatine kinase (creatine inhibits), and the adenine nucleotide translocator (both ATP and ADP inhibit) (Figure 3) . Induction of PT using speci®c drugs, namely protoporphyrin IX (a ligand of the PBR, one of the proteins associated with the PT pore complex) or carbonyl cyanide m-chlorophenylhydra- Figure 3 The PT pore complex in the mitochondrial inner/outer membrane contact site. The localization of dierent proteins in the mitochondrial membranes is depicted. It is not known which among the proteins in the complex are actually involved in the formation of the pore and which are only pore regulators. Moreover, the stoichiometry of the complex and the nature of direct protein-protein interaction is elusive. Direct interactions have been suggested to occur between hexokinase and VDAC and, in addition between VDAC and ANT, but other hypothetical interactions (e.g. between the ANT and cyclophilin D) remain to be demonstrated. Dierent targets for endogenous regulators of apoptosis within the complex are highlighted, and dierent agents that induce (arrows) or block opening of the PT pore are listed. Note the multiplicity of endogenous eectors that act to regulate the PT pore. For references consult the reviews by (Bernardi and Petronilli, 1996; Kroemer et al., 1998; Zoratti and SzaboÁ , 1995) zone (a protonophore that disrupts the proton gradient on the inner mitochondrial membrane) suces to provoke the entire panel of apoptosis-associated metabolic changes, including activation of caspases with caspase 3-like DEVDase activity, redox desequilibria, nuclear DNA fragmentation, and phosphatidylserine exposure on the cell surface Marchetti et al., 1996b; Susin et al., 1997) . In contrast, prevention of PT using substances targeted to mitochondrial structures such as bongkrekic acid (a ligand of the adenine nucleotide translocator of the inner mitochondrial membrane) Zamzami et al., 1996b) or chloromethyl-Xrosamine (a thiol-reactive agent targeted to the mitochondrial matrix) inhibits all apoptotic changes including DEVDase activation by DNA damage, p53 overexpression, or physiological death inducers such as glucocorticoids Polyak et al., 1997) . These data suggest that, at least in these model of apoptosis induction, PT is both necessary and sucient to induce apoptosis.
Molecular composition of the PT pore complex ± copuri®cation with Bax
The exact molecular composition of the pore is not known, although proteins from the cytosol (hexokinase), the outer membrane (peripheral benzodiazepin receptor, mitochondrial porin or voltage-dependent anion channel), the intermembrane space (creatine kinase), the inner membrane (adenine nucleotide translocator, ANT) and the matrix (cyclophilin D) have been implicated in PT pore formation and/or regulation (Beutner et al., 1996; Zoratti and SzaboÁ , 1995) . We have recently puri®ed complexes of hexokinase-associated proteins which we have incorporated into liposomes to reestablish the function of the PT pore in vitro Zamzami et al., 1998) . Biochemical and functional data indicate that the hexokinase-associated polyprotein complex enriched from brain homogenates contains the proapoptotic Bcl-2 homolog Bax (but not Bcl-2 and Bcl-X L ), in addition to proteins previously suggested to participate in the regulation of PT (ANT, VDAC, cyclophilin D, and hexokinase). Using a number of dierent inducers and inhibitors of PT, we found an approximate functional equivalence between the natural (mitochondrial) PT pore and the reconstituted (liposomal) PT pore complex with regard to the way how it regulates membrane permeability (Figure 3) . The functional exploration of PT pore complexes suggests that it contains functionally interconnected sites of interaction with bongkrekic acid and atractyloside (two ligands of the ANT and perhaps other members of the mitochondrial carrier family), cyclosporine A and N-methyl-4-Val-cyclosporine A (two ligands of the cyclophilin D), diamide and monochlorobimane (which act on thiol residues), Ca 2+ , as well as with recombinant caspases, for which the exact substrates remain to be de®ned .
Bax, Bcl-2, and BclX L directly regulate the PT pore complex
In an attempt to identify the molecules actually involved in pore formation, we immunodepleted Bax from the PT pore complex prior to reconstitution into liposomes (Figure 4) . Such Bax-de®cient PT pore liposomes fail to release the¯uorochrome DiOC 6 (3) upon exposure to the ANT ligand atractyloside, whereas in control experiments atractyloside functions on sham-immunodepleted liposomes (manuscript in preparation). Recombinant Bcl-2 and Bcl-X L proteins incorporated into liposomes have an inhibitory eect on PT. The presence of Bcl-X L or Bcl-2 protected against the DiOC 6 (3) release induced by atractyloside, ter-butylhydroperoxide, as well as low doses of Ca 2+ and caspases . A Bcl-2 deletion mutant lacking a putative channel-forming domain corresponding to the a5 and a6 helices, Bcl-2Da5/6, which has lost its anti-apoptotic function (Schendel et al., 1997b) , fails to prevent the DC L disruption . In addition, a Bcl-2 point mutant in the BH1 region, Bcl-2(Gly145Ala), which does not interact with Bax and does not protect against apoptosis (Ying et al., 1994) , has no inhibitory eect on the liposomes containg PT pore complexes (Figure 4 ). These data obtained with puri®ed PT pore complexes con®rm and extend the observation that Bcl-2 prevents PT induced by atractyloside and prooxidants in isolated mitochondria . We have recently shown that this PT-inhibitory eect of Bcl-2 is abolished by the isoquinolinecarboxamide PK11195 (Hirsch et al., 1998b) , a ligand of the 18 kDa mitochondrial benzodiazepin receptor, which interacts with components of the mitochondrial megachannel (McEnery et al., 1992) . Altogether, these biochemical data indicate that Bcl-2-like proteins and PT pores are functionally and molecularly interwoven. Multiple physiological eectors including intermediate metabolites, ion gradients, and redox potentials regulate together the propensity of a pore which requires Bax for its opening, at least in some Figure 4 The puri®ed PT pore complex and its regulation by Bcl-2-related proteins. Membrane hexokinase-associated protein complexes from the rat brain are incorporated into phosphatidylcholine/cholesterol liposomes. Thereafter the capacity of retaining the¯uorochrome DiOC 6 (3) after stimulation with dierent inducers of PT pore opening is assessed using a¯ow cytometric approach Zamzami et al., 1998) . Incorporation of recombinant Bcl-2 or Bcl-X L prevents DiOC 6 (3) release induced by a number of dierent agents that act to induce PT in control liposomes lacking Bcl-2 or Bcl-X L . Mutant Bcl-2 proteins Bcl-2(Gly145Ala) and Bcl-2Da5/6 (D143-184) do not have this eect. Immunodepletion of Bax, which co-puri®es with the PT pore complex, abolishes the atractyloside response. Whereas rec. Bcl-2 or Bcl-X L or depletion of Bax confer resistance to PT pore opening induced by some stimuli, they do not prevent the release of DiOC 6 (3) induced by the thiolcrosslinking agent diamide or high doses of recombinant caspases circumstances, and which is inhibited by Bcl-2 and Bcl-X L (Figures 3 and 4) .
Bax and Bcl-2: limited eects on caspase-and diamide-induced PT pore opening Bcl-2 is a poor inhibitor of apoptosis induced by primary caspase activation or by diamide. Correlating with its cytoprotective eect, Bcl-2 has no eect on diamide induced PT, both in mitochondria and in PT pore complexes reconstituted into liposomes Zamzami et al., 1998) . Similarly, Bcl-2 and Bcl-X L have a limited inhibitory eect on PT pore complexes treated with recombinant caspases. Although Bcl-2 and Bcl-X L reduce PT induced by low doses of recombinant caspases, their inhibitory eect is readily overcome by providing high doses of activated caspases 1, 2, 3, 5 or 6 . These observations correlate with a limited eect of Bax depletion on the functional behavior of PT pore complexes. Bax 7 PT pore complexes maintain their capacity to respond to caspases and to diamide but fail to increase membrane permeability in response to atractyloside (Figure 4 ), indicating that Bax is necessary for some forms of PT but not for others.
Bcl-2 ± primary eect on PT pore complex or on the outer mitochondrial membrane?
It has been a matter of debate whether Bcl-2 would primarily regulate the permeability of the outer mitochondrial membrane or rather primarily aect the PT pore. The strongest argument in favor of a primary eect of Bcl-2 on cytochrome c release rather than on PT pores is based on the observation that, in some cell lines, cytochrome c is liberated into the cytosol of cells before the DC m disruption occurs (Bossy-Wetzel et al., 1998; Kluck et al., 1997a; vander Heiden et al., 1997; Yang et al., 1997) . Unfortunately, the conclusion that cytochrome c is released early, before the DC m disruption occurs, is mostly based on experiments involving rhodamine 123, which is not always appropriate for DC m quantitation (Metivier et al., 1998) . In any case, since the PT pore can function at dierent states of conductance and reversibility (Kinnally et al., 1996; Zoratti and SzaboÁ , 1995) , it is possible that the function of the respiratory chain restores the DC m in conditions in which the PT is¯ickering (Ichas et al., 1997) , although PT pore opening remains the primum movens for an increase in mitochondrial volume and cytochrome c release. In accord with this possibility, it has been found that a PT-mediated reversible loss of the DC m accompanied by cytochrome c release precedes glutamate-induced neuronal apoptosis (Ankarcrona et al., 1995) . Moreover, it has been shown that Bcl-2 can prevent the Ca + -or pro-oxidant-induced disruption of the DC m in isolated mitochondria in conditions in which cytochrome c release is likely not to occur (Shimizu et al., 1998) .
Based on three dierent ®ndings, we thus tend to believe that Bcl-2 regulates cytochrome c release indirectly, via an eect on the PT pore ( Figure 5 ). First, Bcl-2 directly acts on the reconstituted PT pore complex Zamzami et al., 1998) . Second, recombinant Bax added to isolated mitochondria induces both PT and cytochrome c release, and this eect is prevented by the PT inhibitors cyclosporin A and bongkrekic acid (manuscript in preparation). Third, induction of PT in intact mitochondria causes cytochrome c release Kantrow and Piantadosi, 1997; Petit et al., 1998; Scarlett and Murphy, 1997) . Since the reconstituted PT pore complex does not allow for the eux of cytochrome c , another, indirect mechanism must account for cytochrome c release from mitochondria. The most plausible explanation is a PT-mediated in¯ux of ions and water into the mitochondrial matrix leading to the mechanical disruption of the outer mitochondrial membrane. Since the inner mitochondrial membrane has a larger surface area than the outer membrane, upon swelling of the matrix space, the inner membrane can expand until it physically breaks the outer membrane. Thus, a PT pore-mediated increase in matrix volume would indirectly account for the mechanical disruption of the outer membrane, which then causes the release of all soluble intermembrane proteins including cytochrome c (Chernyak, 1997; vander Heiden et al., 1997) .
Interaction of Bcl-2 related proteins with non-related gene products: the adaptor function of Bcl-1
The structure of Bcl-2 ±¯exible loop and BH4
The three-dimensional structure of Bcl-X L monomer in the absence of its carboxy-terminal hydrophobic domain (Bcl-XDTM) consists of two central hydro- Figure 5 Putative relationship between the release of intermembrane proteins and opening of the PT pore. The mitochondrial PT pore can act at several levels of conductance and reversibility. At the low level of conductance, transient opening of the PT pore, followed by action of the respiratory chain leads to a net maintenance of the DC m . However, an augmentation of mitochondrial matrix volume due to H 2 O in¯ux can lead to the local disruption of the outer mitochondrial membrane before the DC m dissipates. In contrast, induction of the irreversible high conductance-mode of the PT pore leads to the quasi-simultaneous disruption of the proton gradient of the inner membrane and the integrity of the outer membrane Bcl-2-like oncoproteins N Zamzami et al phobic helices surrounded by ®ve amphipathic helices, as well as a 60 residue¯exible loop (Muchmore et al., 1996) . This loop (between BH4 and BH3) is highly variable in length among the members of the Bcl-2 gene family, without any apparent correlation with the death-inhibitory or -stimulatory function, and its deletion does not abolish the apoptosis-inhibitory function of Bcl-X L or Bcl-2 (Muchmore et al., 1996; Uhlmann et al., 1996) . It is, however, the target of proteolytic attacks and of phosphorylation events in¯uencing the anti-apoptotic potential of Bcl-2 and Bcl-X L . The c-Jun N-terminal kinase/stress-activated protein kinase (JNK/SAPK) phosphorylates Bcl-2 on residues T56, S70, T74 and S87, within the¯exible loop . It may be speculated that the¯exible loop tethering BH4 to the rest of the molecule may change its conformation upon phosphorylation, thereby regulating the anity of BH4 interactions with other proteins and/or in¯uencing the equilibrium between thè dagger' and globular conformations of Bcl02. Thus, the caspase-3-mediated digestion of the¯exible loop converts Bcl-2 into a death inducer (Cheng et al., 1997) , and the caspase-1-mediated digestion of thē exible loop of Bcl-X L has a similar eect (Clem et al., 1998) Interaction between Bcl-2 and non-related proteins The BH4 domain is conserved among anti-apoptotic Bcl-2 homologs, yet lacks in all proapoptotic members of the Bcl-2 family with the exception of Bcl-X S . This region is not required for protein dimerization in vivo, but its deletion imparts either loss of function (Borner et al., 1994; Hanada et al., 1995) or a dominant negative phenotype, yielding mutants that promote rather than inhibit apoptotic death . In this context, it may be important to note that BH4 is necessary for the interaction of Bcl-2 with Bag-1 and the serine threonine kinase Raf-1 (Wang et al., 1996c) , two molecules which link signal transduction processes to the Bcl-2 complex and in¯uence its antiapoptotic potential (reviewed in Ref. Kroemer, 1997; Reed, 1997) . Bcl-2 also interacts with other proteins not belonging to its family including several proteins with unknown functions (Nip-1,2) (Boyd et al., 1994) , prion protein Pr-1 (Kurschner and Morgan, 1995) , the p53 binding protein BP2 (Naumovski and Cleary, 1996) , the GTPase Ras (Fernandez-Sarabia and Bischo, 1993), calcineurin (Shibasaki et al., 1997) , and carnitine palmitoyl transferase I (Paumen et al., 1997) . The functional relevance of these interactions has not been fully elucidated. Bcl-2 also interacts with the SMN protein, which synergizes with Bcl-2 to inhibit Bax-or CD95-induced apoptosis (Iwahashi et al., 1997) .
Indirect interactions between Bcl-2 and caspases
Recently, two proteins have been shown to interact with Bcl-2, and simultaneously, with caspases, thereby providing a hypothetical link between Bcl-2 and caspase activation. Three such bridging proteins have been described: Apaf-1, which also interacts with cytochrome c and thus may be important for the mitochondrial eects of Bcl-2, p28Bap31, which is an ER membrane protein, and MRIT whose subcellular localization is elusive. The protein Apaf-1 constitutes the structural analog of the nematode death-regulatory protein CED-4 (Zhou et al., 1997) . This pro-apoptotic protein is hold by the nematode analog of Bcl-2, CED-9, on the mitochondrial surface and is released upon induction of apoptosis . It appears that the N-terminus of Bcl-X L , perhaps involving the BH4 domain, is important for interaction with CED-4. Bax (which lacks a BH4 domain) and Bcl-X S (which has a BH4 domain but lacks BH1 and BH2) do not interact with CED4. However, Bax, Bak, and Bik disrupt the interaction between Bcl-X L and CED4 (Chinnaiyan et al., 1997) . Apaf-1 possesses a CARD domain which interacts with a similar domain within the N-terminus of pro-caspase-9 (and pro-caspase-2?). This leads to the formation of a tri-molecular complex containing Bcl-2/Bcl-X L , Apaf-1, and pro-caspase-9, in analogy to the trimolecular complex formed in C. elegans by CED9, CED4 and the pro-caspase CED3 (Spector et al., 1997) . This trimolecular complex has been nick-named the`apoptosome' and may explain most features of cell death regulation in C. elegans (Hengartner, 1997) . It has been speculated that the dissociation of Apaf-1 from Bcl-2/Bcl-X L will initiate a reaction, that, in the presence of cytochrome c and ATP, culminates in the proteolytic activation of caspase-9, which then can activate other caspases (Zhou et al., 1997) . In contrast to Apaf-1, p28Bap31 is a Bcl-2 binding ER membrane protein which associates with pro-caspase-8 . Again, it may be speculated that Bcl-2 inhibits the activation of pro-caspase-8 via p28Bap31 and/or withdraws caspase-8 from its physiological site of activation within plasma membrane-associated receptor complexes built up after ligation of CD95 or its homologs. A similar function may also be ful®led by MRIT, which simultaneously and independenly interacts with Bcl-X L and caspase-8 . These eects may explain how Bcl-2 can, at least in certain circumstances, inhibit caspase activation induced by cytochrome c in intact cells (RosseÂ et al., 1998; Zhivotovsky et al., 1998) .
Conclusion: an integrated view of Bcl-2 function
Eects of Bcl-2 on the three steps of the apoptotic process As discussed above (Table 1) , apoptosis is a multistep process in which Bcl-2 may have several independent roles (Figure 6 ). At the level of the pre-mitochondrial initiation phase, Bcl-2 may in¯uence the translocation of p53 (and of its homologs?) from the cytoplasma to the nucleus, thereby preventing p53 eects on gene transcription. Via eects on Ca 2+ repartition in the ER and the nucleus, Bcl-2 might have an additional eect on signal transduction. Moreover, Bcl-2 may act as an adaptor molecule to withdraw caspases from their site of action. This would be achieved by forming a ternary complex with Apaf-1/Ced-4 (on mitochondria) or p28Bap31 (on the ER) and pro-caspases. However, none of these eects may explain its broad cytoprotective eect, which extends to models of cell death which are p53-independent, do not imply cytoplasmic Ca 2+ elevations, do not require caspase activation, or are not in¯uenced by ER/nucleus-localized Bcl-2. At the mitochondrial eector stage, Bcl-2 apparently inhibits opening of the PT pore via a direct eect on the PT multiprotein complex. By inhibiting PT pore opening, Bcl-2 prevents all mitochondrial manifestations of apoptosis including the disruption of the inner transmembrane potential and the release of apoptogenic proteins via the outer mitochondrial membrane. At this level, Bax acts as a facilitator of PT pore opening and/or constitutes itself a pore. Bcl-2 neutralizes the eect of Bax. In addition, it is possible that, by virtue of its inhibitory eect on caspase activation (via Apaf-1), Bcl-2 interrupts a circular ampli®cation loop involving mitochondria and caspases. The mitochondrial eects of Bcl-2 explain its broad cytoprotective eects in many dierent models of apoptosis and necrosis. At the level of postmitochondrial degradation, Bcl-2 has no eect. Thus, once the mitochondrial eector has been activated, for instance by caspases or diamide which both override the protective eect of Bcl-2 on mitochondria, the cell can commence the degradation phase of apoptosis ( Figure 6 ).
A speculative model linking the pore and the adaptor functions of Bcl-2-like proteins There a little doubts on the dual nature of Bcl-2-like proteins as pore formers and adaptor molecules. However, the relationship between the pore-forming/ pore-inhibitory and adaptor functions of Bcl-2 and Bax Figure 6 Schematic overview of the apoptotic process and the mode of action of Bcl-2. Activation of dierent damage pathways or stimulation of pro-apoptotic signal transduction cascades can have two dierent consequences: (i) perturbation of mitochondrial membrane integrity via activation of the permeability transition pore complex (PTPC) and/or the Bcl-2/Bax complex in the mitochondrial outer/inner membrane contact site or (ii) primary activation of caspase cascades. Bcl-2 and Bax, as well their functional homologs, regulate mitochondrial membrane permeability by virtue of their channel function and/or via indirect eects on the PTPC. Perturbation of outer mitochondrial membrane function leads to the leakage of pro-apoptotic molecules (cytochrome c, AIF) from the intermembrane space into the cytosol, where they participate in the activation of caspases and endonucleases. Cytochrome c interacts with Apaf-1, which is released from Bcl-2. The cytochrome c/Apaf-1/caspase-9 complex then proteolytically activates caspase-3. These molecules (Bcl-2, Apaf-1, which binds ATP, caspase-9, cytochrome c, caspase-3), as well as their structural homologs, constitute the mammalian equivalent of the C. elegans`apoptosome' (CED-9/ CED-4/CED-3 complex). Note that caspases act on unknown mitochondrial membrane substrates to perturb membrane integrity, thereby engaging in a self-ampli®cation loop in which disruption of mitochondrial membrane function causes caspase activation and vice versa. Opening of the permeability transition pore has major eects on energy metabolism and causes generation of reactive oxygen species (double-headed arrows). Cytochrome c release interrupts the transfer of electrons between respiratory chain complexes III and IV, thereby compromising respiratory function and causing the generation of superoxide anion. Bcl-2 can prevent apoptosis via eects on speci®c apoptosis-induction pathways, e.g. by preventing the nuclear translocation of p53 (via its eect on the p53 binding protein 2) or by retaining pro-caspases (pro-caspase 9 via Apaf-1, procaspase-8 via 28Bap31) from their site of action. However, the central role of Bcl-2 consists in the prevention of pore formation by the PTPC and/or Bax. This function appears to be closely related to its capacity to inactivate the`apoptosome' by maintaining the localization of cytochrome c in the intermembrane space and by complexing Apaf-1 to the outer mitochondrial membrane Figure 7 A speculative model for the interrelation between adaptor and pore function of Bcl-2 related proteins. Both Bax and Bcl-2 can exist in two dierent conformations (a helices are symbolized as tubes, see Figure 1 ), a globular`receptor' conformation with juxtaposed a1 through a6 domains and an unfolded conformation in which the a5 and a6 domains insert into the mitochondrial membrane (the`dagger') and the BH3 ligand' domain (=a2 domain) and, in the case of Bcl-2 the BH4 adaptor domain (=a1 domain, lacking in Bax) are freed for the interaction with other proteins. The receptor and the dagger/ adaptor conformations are in equilibrium. Heterodimerization of Bax and Bcl-2 occurs in a asymmetric fashion, one molecule being in the receptor and the other in the unfolded conformation. Bax (but probably not Bcl-2) can form an oligomeric structure leading to the juxtaposition of several a5/a6`daggers' into the membrane which together form a lethal pore (or aid to form a pore, in conjunction with other proteins of the PT pore complex), within the inner/outer membrane contact site of the mitochondrion). The model proposes how pore formation by Bax may be connected with the loss of the adaptor function of Bcl-2, leading to the release of Apaf-1 (which interacts with the N-terminal portion of Bcl-2) and the activation of the`apoptosome' (Figure 7) . Any circumstance that leads to an increase in the concentration of potentially pore-forming Bax, must withdraw globular Bcl-2 from the equilibrium state, thereby ultimately reducing the amount of Bcl-2 available for the adaptor function is an ongoing conundrum. How is it possible to couple PT pore opening (which is facilitated by Bax and inhibited by Bcl-2 and Bcl-X L ) to the Apaf-1/caspase-9 release culminating in the activation of the caspase cascade? As discussed above, both Bax-like death agonists and Bcl-2-like death antagonists are likely to exist in two conformations, a globular`receptor' structure with closely packed BH1 through BH4 domains, and an unfolded`dagger' structure which can produce pores (at least in the case of Bax) and, simultaneously liberates the BH3 domain (which can form a`ligand' for the globular`receptor' formed by BH1, BH2, and BH3) and the BH4 domain (which interacts with Ced-4 as well as with apoptosisinhibitory molecules such as Bag-1 and Raf-1). Considering the asymmetric relationship between dierent members of the Bcl-2 family, this could imply that any increase in the concentration of the pore-forming`dagger' structure of Bax (which can interact with the globular`receptor' structure of Bcl-2) might be accompanied by the trapping of Bcl-2 into the globular conformation, thereby reducing the amount of the`dagger' type of Bcl-2, which would entail the release of Apaf-1/caspase 9 complexes from the mitochondrial surface. Addition of BH3-like peptides would disrupt the neutralizing interaction between Bcl-2 and Bax and again trap Bcl-2 into the globular conformation (Figure 7) . Future studies will tell to which degree this simple (simplistic?) model will withstand experimental veri®cation and will require sophistication. In particular, it will be necessary to determine the relative abundance of particular Bcl-2/ Bax-containing protein complexes, the association and dissociation rates of each of these complexes, as well as their relative function. Moreover, the intriguing functional and physical interaction between the Bcl-2/ Bax complex and the PT pore complex awaits further elucidation.
Abbreviations AIF, apoptosis-inducing factor; DYC m , mitochondrial transmembrane potential; diamide, diazenedicarboxylic acid bis 5N,N-dimethylamide; ER, endoplasmic reticulum; PT, permeability transition; ROS, reactive oxygen species; Z-VAD.fmk, N-benzyloxycarbonyl-Val-Ala-Asp-fluoromethylketone
